Petros pharmaceuticals strengthens partnership with market leading big data provider implementing key enhancements to its ai platform

Company continues to innovate and develop its saas-based platform to facilitate rx-to-otc switch in line with recent president trump executive order new york, ny / access newswire / may 6, 2025 / petros pharmaceuticals, inc. (nasdaq:ptpi) ("petros" or the "company"), a company focused on expanding consumer access to medication through over the counter ("otc") drug development programs, today announces it has implemented multiple enhancements to its developing ai platform, which is expected to improve processing and fraud detection and provide a better overall experience. the ai platform is expected to be a key component of the company's recently announced saas-based technology, integrating petros' software as a medical device ("samd") proprietary solution, which is being designed to help facilitate expanding access for established prescription drugs by bringing them over the counter.
PTPI Ratings Summary
PTPI Quant Ranking